Sign in
Taking people in CzechiaPhase 4

Compares two anti-rejection drugs after pancreas and kidney transplant in type 1 diabetes

Tests sirolimus versus mycophenolate in adults with type 1 diabetes and kidney failure.

Key facts

Who runs it
Institute For Clinical And Experimental Medicine
Where
Prague, CzechiaSee the site
Registry title
SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA
Status
Recruiting
Phase
Phase 4
People taking part
120 people, planned
Started
9 Sept 2020
Expected to end
31 May 2028
Type of study
Interventional
Record updated
8 October 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 diabetes and advanced kidney failure who are due to be listed for a combined pancreas and kidney transplant from a deceased donor.

Age
18 to 65 years (the registry also lists a maximum age of 64 years)
Sex
Men and women can join.
Disease stage
Pre-end-stage or end-stage kidney failure caused by type 1 diabetes.
Earlier treatment
Cannot have had a previous kidney transplant alone. Cannot have had a major abdominal operation or a hernia in the abdominal wall.
Biomarker or test result
Cannot have a positive T-cell cross-match on the latest blood sample. Cannot have a high immune risk (PRA above 50%).

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Allergy or intolerance to any drug in either treatment plan
  • Active or significant liver disease
  • Cancer now or in the past (except treated localized skin cancer without return)
  • Kidney from a living donor, a partial pancreas transplant, or donor older than 65 years

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • 1 Male or female patients, of 18 to 65 years of age, with a pre- or an end-stage renal failure, Type 1-diabetic nephropathy
  • Patient is scheduled to be put on waiting-list for a primary simultaneous pancreas/kidney (SPK) cadaver transplant

Who cannot take part

  • Patient receives a kidney transplant from a living donor, or receives segmental pancreatic transplant, or a previous kidney transplant alone
  • Patient has a history of an extensive abdominal operation or a hernia in the abdominal wall
  • Patient is allergic or intolerant to any drug comprising both immunosuppressive protocols
  • Patient has malignancy or history of malignancy, with the exception of adequately treated localized squamous cell or basal cell carcinoma, without recurrence
  • Patient has any form of substance abuse, psychiatric disorder or condition, which, in the opinion of the investigator, may invalidate communication
  • Patient has a positive T-cell cross-match on the most recent serum specimen
  • Patient is known for active liver disease or has significant liver disease; defined by ASAT and ALAT serum levels greater than 3 times the upper limit of normal
  • Donor is older than 65 years of age
  • Patient is pregnant or breastfeeding
  • Patient has a high immunological risk, defined as a PRA grade > 50%

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Czechia

  • Institute for Clinical and Experimental MedicinePrague, CzechiaTaking people

About the trial

What the trial wants to find out

To compare the incidence of incisional hernia following combined pancreas and kidney transplantation in type 1 diabetic subjects with end-stage kidney disease treated with to different immunosuppressive rengimens

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA
Plain-language title
Compares two anti-rejection drugs after pancreas and kidney transplant in type 1 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 11 November 2026.
Criteria questions
Built from 2024-517391-38-00, who can take part
Record updated
8 October 2024